Cryo-Cell International, Inc. Fundamental Analysis (AMEX: CCEL)
Cryo-Cell International, Inc. Fundamental Analysis (AMEX: CCEL)
Cryo-Cell International, Inc. (AMEX: CCEL) shows moderate financial fundamentals with a PE ratio of -22.26, profit margin of -9.05%, and ROE of 15.84%. The company generates $0.0B in annual revenue with weak year-over-year growth of -1.31%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 33.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze CCEL's fundamental strength across five key dimensions:
Efficiency Score
WeakCCEL struggles to generate sufficient returns from assets.
Valuation Score
ExcellentCCEL trades at attractive valuation levels.
Growth Score
WeakCCEL faces weak or negative growth trends.
Financial Health Score
ModerateCCEL shows balanced financial health with some risks.
Profitability Score
ModerateCCEL maintains healthy but balanced margins.
Key Financial Metrics
Is CCEL Expensive or Cheap?
P/E Ratio
CCEL trades at -22.26 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, CCEL's PEG of 0.06 indicates potential undervaluation.
Price to Book
The market values Cryo-Cell International, Inc. at -2.45 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 34.36 times EBITDA. This signals the market has high growth expectations.
How Well Does CCEL Make Money?
Net Profit Margin
For every $100 in sales, Cryo-Cell International, Inc. keeps $-9.05 as profit after all expenses.
Operating Margin
Core operations generate 0.61 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $15.84 in profit for every $100 of shareholder equity.
ROA
Cryo-Cell International, Inc. generates $-4.52 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Cryo-Cell International, Inc. produces operating cash flow of $4.92M, showing steady but balanced cash generation.
Free Cash Flow
Cryo-Cell International, Inc. generates strong free cash flow of $4.65M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.58 in free cash annually.
FCF Yield
CCEL converts 11.41% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-22.26
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.06
vs 25 benchmark
P/B Ratio
Price to book value ratio
-2.45
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.29
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-0.04
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.86
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.16
vs 25 benchmark
ROA
Return on assets percentage
-0.05
vs 25 benchmark
ROCE
Return on capital employed
0.004
vs 25 benchmark
How CCEL Stacks Against Its Sector Peers
| Metric | CCEL Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -22.26 | 31.47 | Better (Cheaper) |
| ROE | 15.84% | 507.00% | Weak |
| Net Margin | -9.05% | -4103644.00% (disorted) | Weak |
| Debt/Equity | -0.04 | 0.00 | Distorted |
| Current Ratio | 0.86 | 5.79 | Weak Liquidity |
| ROA | -4.52% | -262.00% (disorted) | Weak |
CCEL outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Cryo-Cell International, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
2.24%
Industry Style: Defensive, Growth, Innovation
GrowingEPS CAGR
-167.62%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-34.72%
Industry Style: Defensive, Growth, Innovation
Declining